School of Life Sciences, Tsinghua University, Key Laboratory for Protein Sciences of MOE, Beijing 100084, China.
J Virol. 2012 Jan;86(1):589-93. doi: 10.1128/JVI.05066-11. Epub 2011 Oct 19.
To prove that the peptidic HIV-1 fusion inhibitors containing the pocket-binding domain (PBD) mainly target the hydrophobic pocket in the gp41 N-terminal heptad repeat (NHR), we constructed pseudoviruses by replacement of Q64 in the gp41 pocket region with Ala (Q64A) or Leu (Q64L). These viruses were highly resistant to C34 and CP32M containing the PBD, while they were susceptible to T20 (enfuvirtide) lacking the PBD but containing the GIV-motif-binding domain (GBD) and lipid-binding domain (LBD). They were also sensitive to C52L, which contains the PBD, GBD, and LBD. Those mutations may disrupt the hydrophilic interaction between Q64 in the NHR and N113 in the peptides containing the PBD. This report provides insights into the mechanisms of drug resistance, with implications for the design of novel HIV fusion and entry inhibitors.
为了证明含有口袋结合域(PBD)的肽类 HIV-1 融合抑制剂主要靶向 gp41 N 端七肽重复(NHR)中的疏水性口袋,我们用丙氨酸(Q64A)或亮氨酸(Q64L)替换了 gp41 口袋区域的 Q64,构建了假病毒。这些病毒对含有 PBD 的 C34 和 CP32M 高度耐药,但对缺乏 PBD 但含有 GIV 基序结合域(GBD)和脂质结合域(LBD)的 T20(恩夫韦肽)敏感。它们也对含有 PBD、GBD 和 LBD 的 C52L 敏感。这些突变可能破坏了 NHR 中的 Q64 和含有 PBD 的肽中的 N113 之间的亲水相互作用。本报告深入了解了耐药机制,为设计新型 HIV 融合和进入抑制剂提供了思路。